Clinical Trials Logo

Randomized Clinical Trial clinical trials

View clinical trials related to Randomized Clinical Trial.

Filter by:

NCT ID: NCT03026049 Terminated - Clinical trials for Randomized Clinical Trial

Stent Versus Conservative Treatment in Patients With Deep Venous Obstruction

STEVECO
Start date: March 9, 2017
Phase: N/A
Study type: Interventional

Patients will be randomised between deep venous stenting or conservative management

NCT ID: NCT01269567 Completed - Clinical trials for Randomized Clinical Trial

Drainage After Rectal Excision for Rectal Cancer

GRECCAR 5
Start date: January 2011
Phase: Phase 3
Study type: Interventional

After rectal excision, the rate of anastomotic leak and abscess is higher than after colic surgery. In order to limit and avoid the risk of pelvic sepsis after rectal excision, a prophylactic pelvic drainage is usually used. If current data have confirmed the uselessness of drainage in colic surgery, the question stay in abeyance in rectal surgery. This practice had never been evaluated in patients with rectal excision and low anastomosis (patients with a high risk of pelvic sepsis)

NCT ID: NCT00589953 Terminated - Brain Injury Clinical Trials

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The highest risk for perinatal brain injury occurs among extremely premature infants who weigh less than 1250 grams at birth. Such perinatal brain injury is currently irreversible, associated with neurodevelopmental disability, and without adequate treatment modalities. Research in recent years suggest in both animal and human studies that erythropoietin (Epo) may have significant neuroprotective effects. Given the historical safe medical profile of Epo when used for anemia of prematurity but the likely need for a greater dosage regimen for activation of neuroprotective pathways against neonatal brain injury, we therefore propose this phase II study of high-dose Epo in very low birth weight infants for the prevention and/or attenuation of prematurity-related cerebral hemorrhagic-ischemic injury.